Progenics Pharms Inc Drug Patent Portfolio

Progenics Pharms Inc owns 1 orange book drug protected by 5 US patents Given below is the list of Progenics Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10947197 Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL 09 Jun, 2037
Active
US11851407 Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL 09 Jun, 2037
Active
US8778305 PSMA-binding agents and uses thereof 21 Sep, 2030
Active
US9861713 PSMA-binding agents and uses thereof 31 Jul, 2029
Active
US8487129 Heterodimers of glutamic acid 07 Nov, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Progenics Pharms Inc.

Activity Date Patent Number
Patent litigations
Email Notification 26 Dec, 2023 US11851407
Recordation of Patent eGrant 26 Dec, 2023 US11851407
Recordation of Patent Grant Mailed 26 Dec, 2023 US11851407
Patent Issue Date Used in PTA Calculation 26 Dec, 2023 US11851407
Mail Patent eGrant Notification 26 Dec, 2023 US11851407
Patent eGrant Notification 26 Dec, 2023 US11851407
Email Notification 07 Dec, 2023 US11851407
Issue Notification Mailed 06 Dec, 2023 US11851407
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US8778305
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US8487129
transaction for FDA Determination of Regulatory Review Period 30 Nov, 2023 US9861713
transaction for FDA Determination of Regulatory Review Period 29 Nov, 2023 US8487129
transaction for FDA Determination of Regulatory Review Period 29 Nov, 2023 US9861713
transaction for FDA Determination of Regulatory Review Period 29 Nov, 2023 US8778305
Dispatch to FDC 14 Nov, 2023 US11851407


Progenics Pharms Inc Drug Patents' Oppositions Filed in EPO

Progenics Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 23, 2021, by Lewis Silkin Llp. This opposition was filed on patent number EP18150494A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP19214298A Jan, 2023 Telix Innovations S.A. Granted and Under Opposition
EP18150494A Sep, 2021 Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg Revoked
EP18150494A Sep, 2021 POLSERVICE KANCELARIA RZECZNIKOW PATENTOWYCH SP. Z O.O. Revoked
EP18150494A Sep, 2021 Lewis Silkin LLP Revoked


Progenics Pharms Inc's Family Patents

Progenics Pharms Inc drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 29.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Progenics Pharms Inc Drug List

Given below is the complete list of Progenics Pharms Inc's drugs and the patents protecting them.


1. Pylarify

Pylarify is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10947197 Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL 09 Jun, 2037
(12 years from now)
Active
US11851407 Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL 09 Jun, 2037
(12 years from now)
Active
US8778305 PSMA-binding agents and uses thereof 21 Sep, 2030
(5 years from now)
Active
US9861713 PSMA-binding agents and uses thereof 31 Jul, 2029
(4 years from now)
Active
US8487129 Heterodimers of glutamic acid 07 Nov, 2027
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pylarify's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List